Anuradha Lala-Trindade

Featured in: Favicon

medscape.com Favicon

hcplive.com

Articles

Use Social Media as a Force of Light in Cardiology

Jan 16, 2024 | medscape.com | Michelle M. Kittleson |Anuradha Lala-Trindade |Robert J. Mentz

Authors and Disclosures Michelle M. Kittleson, MD, PhD Professor of Medicine, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CaliforniaDisclosure: Michelle M. Kittleson, MD, PhD, has disclosed no relevant financial relationships.
The Future of Heart Failure Therapy

Jul 31, 2023 | hcplive.com | Anuradha Lala-Trindade

Anuradha Lala-Trindade, MD: I’m excited about a lot in heart failure. I’m always excited about heart failure. I’m excited about a couple of things, depending on the realm of heart failure we’re talking about. So, I’m excited about implementation strategies and leveraging data science and electronic health record-based technology to optimize guideline-directed medical therapy.
Clinical Trials of Sacubitril/Valsartan in Heart Failure

Jul 31, 2023 | hcplive.com | Anuradha Lala-Trindade

Anuradha Lala-Trindade, MD: Recently we’ve gained information as to the effects of sacubitril/valsartan on NT-proBNP [N-terminal prohormone of brain natriuretic peptide] amongst patients with acute heart failure. So, these were not patients who were included in the PARAGON-HF study who had chronic heart failure with preserved ejection fraction [HFpEF], nor quite frankly, was there an adequate representation of individuals of Black race in PARAGON-HF, as well.
Unmet Needs in the Management of Heart Failure

Jul 24, 2023 | hcplive.com | Anuradha Lala-Trindade

Anuradha Lala-Trindade, MD: I think current unmet needs for patients with mildly reduced or preserved ejection fraction are as follows. Despite the advent of SGLT2 [sodium-glucose cotransporter-2] inhibitors, which are so efficacious in this population, I think we still have a lot to learn as to how to better characterize these patients and not lump them all together.
Personalizing Quadruple Therapy in Heart Failure

Jul 24, 2023 | hcplive.com | Anuradha Lala-Trindade

Anuradha Lala-Trindade, MD: In terms of how to respond or treat a patient with heart failure with reduced ejection fraction [HFrEF]. First, I take a really thorough family history. I take a history of from when they were a child through adolescence and young adulthood into adulthood, because I think it speaks a lot to how they were brought up, what their habits were in terms of exercise and diet and otherwise, whether they were hospitalized or chronically ill from an early age on or not.
Use of SGLT-2 Inhibitors in Heart Failure

Jul 17, 2023 | hcplive.com | Anuradha Lala-Trindade

Anuradha Lala-Trindade, MD: SGLT2 [sodium-glucose cotransporter-2] inhibitors are not the new kid on the block anymore, but it has been an exceedingly exciting time in heart failure by virtue of this class of drugs. There are a number of trials that have shown us the efficacy of these drugs in the treatment of heart failure across the spectrum of ejection fraction and across different settings of heart failure. So, acute heart failure as well as chronic heart failure.
Quadruple Therapy for Patients With Heart Failure

Jul 17, 2023 | hcplive.com | Anuradha Lala-Trindade

Discussing the foundational pillars of quadruple-based guideline directed medical therapy for heart failure with reduced ejection fraction is the new standard. That is really important. New or not so new, quite frankly, it is the standard. So, the 4 pillars of guideline-directed medical therapy are constituted of an ARNi [angiotensin receptor/neprilysin inhibitor], followed by an ACE [angiotensin converting enzyme] inhibitor or an ARB [angiotensin receptor blocker].
Prevalence and Risk Factors of Heart Failure

Jul 10, 2023 | hcplive.com | Anuradha Lala-Trindade

Anuradha Lala-Trindade, MD: I think our understanding as to the prevalence of heart failure across the spectrum of ejection fraction has evolved tremendously over the past decade. We used to think heart failure with reduced ejection fraction was the only really meaningful heart failure. And what we know now from large registry and observational studies is that the prevalence of heart failure with reduced ejection fraction and preserved ejection fraction is actually equivalent.
Challenges in Heart Failure Management

Jul 10, 2023 | hcplive.com | Anuradha Lala-Trindade

Anuradha Lala-Trindade, MD: Managing heart failure in the United States is riddled with challenges. I tend to be an optimist, but we have to call a spade a spade. I think there are several aspects of why it is so challenging to manage heart failure. One, I think we recognize that hospitalizations for heart failure are exceedingly common. It's the most common reason for hospitalization in patients over the age of 65.